Home » Stocks » Oyster Point Pharma

Oyster Point Pharma, Inc. (OYST)

Stock Price: $24.93 USD -0.95 (-3.67%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 642.02M
Revenue (ttm) n/a
Net Income (ttm) -63.20M
Shares Out 25.69M
EPS (ttm) -21.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $24.93
Previous Close $25.88
Change ($) -0.95
Change (%) -3.67%
Day's Open 26.42
Day's Range 24.91 - 26.80
Day's Volume 35,835
52-Week Range 13.26 - 41.37

More Stats

Market Cap 642.02M
Enterprise Value 416.09M
Earnings Date (est) Dec 8, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.69M
Float 9.16M
EPS (basic) -1.13
EPS (diluted) -21.22
FCF / Share -2.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 644,230
Short Ratio 6.87
Short % of Float 7.75%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.97
Revenue n/a
Operating Income -64.48M
Net Income -63.20M
Free Cash Flow -51.87M
Net Cash 225.93M
Net Cash / Share 8.77
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.36%
ROE -41.42%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$63.25*
(153.71% upside)
Low
57.0
Current: $24.93
High
71.0
Target: 63.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-47.30-16.74-5.68
Net Income-45.71-16.50-6.60
Shares Outstanding4.591.411.41
Earnings Per Share-9.97-11.69-13.56
Operating Cash Flow-40.82-17.08-4.67
Capital Expenditures-0.20--
Free Cash Flow-41.02-17.08-4.67
Cash & Equivalents1395.2322.31
Total Debt0.810.06-
Net Cash / Debt1385.1722.31
Assets1435.7023.17
Liabilities5.910.952.07
Book Value137-38.24-21.89
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oyster Point Pharma, Inc.
Country United States
Employees 30
CEO Jeffrey A. Nau

Stock Information

Ticker Symbol OYST
Stock Exchange NASDAQ
Unique Identifier NASDAQ: OYST
IPO Date October 31, 2019

Description

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.